Finch Therapeutics Group, Inc. (FNCHQ): Nasdaq/NYSE listing notice — Finch Therapeutics receives Nasdaq deficiency notice for MVPHS below $5M

Finch Therapeutics Group, Inc.

Received Nasdaq deficiency letter Nov 15, 2023 for failing MVPHS Rule 5450(b)(1)(C) for 35 consecutive days.
Market value of publicly held shares below $5M minimum required for continued listing on Nasdaq Global Select Market.
Compliance period through May 13, 2024; must meet $5M threshold for 10 consecutive business days to regain compliance.
If non-compliant, company may consider transferring to Nasdaq Capital Market; delisting possible if not cured.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.98

Finch Therapeutics Group, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(1)(C)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: market value
Rules: 5450(b)(1)(C)

Exact text from the filing

November 15, 2023, Finch Therapeutics Group, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 35 consecutive business days, it did not meet the requirement to have a market value of publicly held shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), of $5.0 million pursuant to Nasdaq Listing Rule 5450(b)(1)(C) (the “MVPHS Rule”). The deficiency letter has no immediate effect on the listing of the Common Stock on the Nasdaq Global Select

View on SEC.gov

Browse all listing & compliance notices →

Finch Therapeutics Group, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-279821

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.